Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Crinetics reports Q1 EPS (69c), consensus (66c) » 17:14
05/06/21
05/06
17:14
05/06/21
17:14
CRNX

Crinetics

$16.72 /

-0.41 (-2.39%)

Unrestricted cash, cash…

Unrestricted cash, cash equivalents and investments totaled $150.7M as of March 31, compared to $170.9M as of December 31, 2020. The cash balance at the end of March does not include the $72.5M of net proceeds from the follow-on offering completed in April. "In the first quarter we achieved key clinical and regulatory milestones across our pipeline," said Scott Struthers, founder and CEO of Crinetics. "Based on our interactions with the FDA and other regulators, we developed a robust Phase 3 program for paltusotine that is designed to support its approval for all acromegaly patients who require pharmacotherapy, including both untreated patients and those switching from injected standard of care. This progress was complemented by the advancement of CRN04894 and CRN04777 into Phase 1 trials in healthy volunteers, which are designed to generate safety, pharmacokinetic, and biomarker data that could establish clinical proof of concept and provide important dose guidance information for subsequent trials in patients. Looking ahead, we are on track for a steady cadence of catalysts through the remainder of the year, including data from both of our Phase 1 trials and the initiation of a clinical study in patients with neuroendocrine tumors complicated by carcinoid syndrome."

ShowHide Related Items >><<
CRNX Crinetics
$16.72 /

-0.41 (-2.39%)

CRNX Crinetics
$16.72 /

-0.41 (-2.39%)

05/03/21 JonesTrading
Crinetics initiated with a Buy at JonesTrading
11/24/20 Piper Sandler
Crinetics could take 'sizable share' in $3.1B market, says Piper Sandler
11/23/20 Cantor Fitzgerald
Crinetics price target raised to $42 from $38 at Cantor Fitzgerald
10/26/20 Piper Sandler
ACROBAT data improve odds of Phase 3 success for Crinetics, says Piper Sandler
CRNX Crinetics
$16.72 /

-0.41 (-2.39%)

  • 08
    Apr
CRNX Crinetics
$16.72 /

-0.41 (-2.39%)

Over a week ago
Initiation
Crinetics initiated with a Buy at JonesTrading » 06:36
05/03/21
05/03
06:36
05/03/21
06:36
CRNX

Crinetics

$17.28 /

-0.54 (-3.03%)

JonesTrading analyst Lina…

JonesTrading analyst Lina Kaminski initiated coverage of Crinetics with a Buy rating and $42 price target. The company's late-stage asset paltusotine is a "best-in class" oral therapy with the potential to address all acromegaly patients who require pharmacotherapy, said Kaminski, who also sees paltusotine's expansion into neuroendocrine tumors as "the next logical step" and views that program as "fairly de-risked."

ShowHide Related Items >><<
CRNX Crinetics
$17.28 /

-0.54 (-3.03%)

CRNX Crinetics
$17.28 /

-0.54 (-3.03%)

11/24/20 Piper Sandler
Crinetics could take 'sizable share' in $3.1B market, says Piper Sandler
11/23/20 Cantor Fitzgerald
Crinetics price target raised to $42 from $38 at Cantor Fitzgerald
10/26/20 Piper Sandler
ACROBAT data improve odds of Phase 3 success for Crinetics, says Piper Sandler
10/14/20 JPMorgan
Crinetics resumed with a Neutral at JPMorgan
CRNX Crinetics
$17.28 /

-0.54 (-3.03%)

  • 08
    Apr
CRNX Crinetics
$17.28 /

-0.54 (-3.03%)

Over a month ago
Syndicate
Crinetics 4.56M share Spot Secondary priced at $16.44 » 18:35
04/07/21
04/07
18:35
04/07/21
18:35
CRNX

Crinetics

$16.46 /

-0.04 (-0.24%)

SVB Leerink is acting as…

SVB Leerink is acting as sole book running manager for the offering.

ShowHide Related Items >><<
CRNX Crinetics
$16.46 /

-0.04 (-0.24%)

CRNX Crinetics
$16.46 /

-0.04 (-0.24%)

11/24/20 Piper Sandler
Crinetics could take 'sizable share' in $3.1B market, says Piper Sandler
11/23/20 Cantor Fitzgerald
Crinetics price target raised to $42 from $38 at Cantor Fitzgerald
10/26/20 Piper Sandler
ACROBAT data improve odds of Phase 3 success for Crinetics, says Piper Sandler
10/14/20 JPMorgan
Crinetics resumed with a Neutral at JPMorgan
CRNX Crinetics
$16.46 /

-0.04 (-0.24%)

  • 15
    Apr
CRNX Crinetics
$16.46 /

-0.04 (-0.24%)

On The Fly
Fly Intel: After-Hours Movers » 19:05
03/30/21
03/30
19:05
03/30/21
19:05
RMO

Romeo Power

$10.35 /

-0.53 (-4.87%)

, MILE

Metromile

$11.22 /

-0.21 (-1.84%)

, CRNX

Crinetics

$15.45 /

-0.2 (-1.28%)

, BB

BlackBerry

$9.34 /

+0.13 (+1.41%)

, EDAP

EDAP TMS

$9.55 /

-0.13 (-1.34%)

, BEEM

Beam Global

$37.15 /

+1.85 (+5.24%)

, APR

Apria

$25.61 /

+0.63 (+2.52%)

, CAAP

Corporacion America Airport

$4.95 /

+0.24 (+5.10%)

, LULU

Lululemon

$317.46 /

+1.37 (+0.43%)

, NMTR

9 Meters Biopharma

$1.37 /

+0.035 (+2.63%)

, CHWY

Chewy

$80.39 /

+1.6 (+2.03%)

, HYFM

Hydrofarm

$53.10 /

+1.16 (+2.23%)

, PHR

Phreesia

$52.25 /

+1.46 (+2.87%)

, PVH

PVH Corp.

$100.25 /

+2.26 (+2.31%)

, PRPH

ProPhase Labs

$6.29 /

+0.06 (+0.96%)

, SURF

Surface Oncology

$7.25 /

-0.7 (-8.81%)

, CASI

Casi Pharmaceuticals

$1.98 /

-0.01 (-0.50%)

, CLF

Cleveland-Cliffs

$17.25 /

+1.01 (+6.22%)

, SLCA

U.S. Silica

$11.88 /

+0.195 (+1.67%)

, AVO

Mission Produce

$18.05 /

-0.3801 (-2.06%)

Check out this evening's…

ShowHide Related Items >><<
SURF Surface Oncology
$7.25 /

-0.7 (-8.81%)

SLCA U.S. Silica
$11.88 /

+0.195 (+1.67%)

RMO Romeo Power
$10.35 /

-0.53 (-4.87%)

PVH PVH Corp.
$100.25 /

+2.26 (+2.31%)

PRPH ProPhase Labs
$6.29 /

+0.06 (+0.96%)

PHR Phreesia
$52.25 /

+1.46 (+2.87%)

NMTR 9 Meters Biopharma
$1.37 /

+0.035 (+2.63%)

MILE Metromile
$11.22 /

-0.21 (-1.84%)

LULU Lululemon
$317.46 /

+1.37 (+0.43%)

HYFM Hydrofarm
$53.10 /

+1.16 (+2.23%)

EDAP EDAP TMS
$9.55 /

-0.13 (-1.34%)

CRNX Crinetics
$15.45 /

-0.2 (-1.28%)

CLF Cleveland-Cliffs
$17.25 /

+1.01 (+6.22%)

CHWY Chewy
$80.39 /

+1.6 (+2.03%)

CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

CAAP Corporacion America Airport
$4.95 /

+0.24 (+5.10%)

BEEM Beam Global
$37.15 /

+1.85 (+5.24%)

BB BlackBerry
$9.34 /

+0.13 (+1.41%)

AVO Mission Produce
$18.05 /

-0.3801 (-2.06%)

APR Apria
$25.61 /

+0.63 (+2.52%)

RMO Romeo Power
$10.35 /

-0.53 (-4.87%)

03/08/21 Cowen
Cowen bullish on battery technology, starts Romeo Power at Outperform
03/08/21 Cowen
Romeo Power initiated with an Outperform at Cowen
02/11/21 Morgan Stanley
Romeo Power initiated with an Underweight at Morgan Stanley
MILE Metromile
$11.22 /

-0.21 (-1.84%)

CRNX Crinetics
$15.45 /

-0.2 (-1.28%)

11/24/20 Piper Sandler
Crinetics could take 'sizable share' in $3.1B market, says Piper Sandler
11/23/20 Cantor Fitzgerald
Crinetics price target raised to $42 from $38 at Cantor Fitzgerald
10/26/20 Piper Sandler
ACROBAT data improve odds of Phase 3 success for Crinetics, says Piper Sandler
10/14/20 JPMorgan
Crinetics resumed with a Neutral at JPMorgan
BB BlackBerry
$9.34 /

+0.13 (+1.41%)

02/16/21
Fly Intel: Top five analyst downgrades
02/16/21 Canaccord
BlackBerry cut to Sell after 'targeted short squeeze' at Canaccord
02/16/21 Canaccord
BlackBerry downgraded to Sell from Hold at Canaccord
01/27/21 Scotiabank
Scotiabank downgrades BlackBerry to Underperform after 'overdone' rally
EDAP EDAP TMS
$9.55 /

-0.13 (-1.34%)

01/25/21 Lake Street
EDAP TMS initiated with a Buy at Lake Street
01/22/21 B. Riley
EDAP TMS price target raised to $13 from $11.50 at B. Riley Securities
01/12/21 B. Riley
EDAP TMS price target raised to $11.50 from $5.50 at B. Riley Securities
04/15/20
Fly Intel: Top five analyst initiations
BEEM Beam Global
$37.15 /

+1.85 (+5.24%)

03/08/21 Cowen
Beam Global initiated with a Market Perform at Cowen
02/05/21 Roth Capital
Beam Global initiated with a Buy at Roth Capital
12/29/20 Maxim
Maxim boosts Beam Global price target to $90 on EV charging products
12/29/20 Maxim
Beam Global price target raised to $90 from $45 at Maxim
APR Apria
$25.61 /

+0.63 (+2.52%)

03/24/21 Citi
CMS oxygen rate change may drive upside for Apria, says Citi
03/08/21 Citi
Apria initiated with a Buy at Citi
03/08/21 Goldman Sachs
Apria initiated with a Buy at Goldman Sachs
03/08/21 Piper Sandler
Apria initiated with an Overweight at Piper Sandler
CAAP Corporacion America Airport
$4.95 /

+0.24 (+5.10%)

04/08/20 Goldman Sachs
Corporacion America Airport downgraded to Neutral from Buy at Goldman Sachs
LULU Lululemon
$317.46 /

+1.37 (+0.43%)

03/29/21 Piper Sandler
Lululemon selloff brings 'compelling entry point,' says Piper Sandler
03/17/21 Morgan Stanley
Lululemon price target lowered to $386 from $400 at Morgan Stanley
03/15/21 Cowen
Lululemon price target lowered to $389 from $409 at Cowen
01/13/21 Morgan Stanley
Lululemon price target raised to $400 from $381 at Morgan Stanley
NMTR 9 Meters Biopharma
$1.37 /

+0.035 (+2.63%)

03/25/21 Brookline
9 Meters Biopharma assumed with a Buy at Brookline
01/28/21 Oppenheimer
9 Meters Biopharma initiated with an Outperform at Oppenheimer
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Maxim
9 Meters Biopharma initiated with a Buy at Maxim
CHWY Chewy
$80.39 /

+1.6 (+2.03%)

03/25/21 Cleveland Research
Chewy Q4 net sales estimate raised after checks at Cleveland Research
03/25/21 JPMorgan
JPMorgan positive on Chewy fundamentals into Q4 report
03/09/21 Citi
Citi starts Best Buy with Sell, sees 'too many red flags'
03/08/21 Citi
Chewy initiated with a Neutral at Citi
HYFM Hydrofarm
$53.10 /

+1.16 (+2.23%)

02/22/21 Truist
Hydrofarm price target raised to $95 from $65 at Truist
01/04/21 William Blair
Hydrofarm initiated with an Outperform at William Blair
01/04/21 Truist
Hydrofarm initiated with a Buy at Truist
01/04/21 Deutsche Bank
Hydrofarm initiated with a Buy at Deutsche Bank
PHR Phreesia
$52.25 /

+1.46 (+2.87%)

01/14/21 Needham
Phreesia price target raised to $70 from $60 at Needham
01/08/21 Baird
Vocera downgraded to Neutral on valuation at Baird
01/04/21 Stephens
Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
12/14/20 Citi
Phreesia price target raised to $59 from $33 at Citi
PVH PVH Corp.
$100.25 /

+2.26 (+2.31%)

03/29/21 Piper Sandler
PVH Corp. price target raised to $109 from $93 at Piper Sandler
01/27/21 Citi
PVH Corp. price target raised to $105 from $92 at Citi
01/21/21 Deutsche Bank
PVH Corp. price target raised to $112 from $87 at Deutsche Bank
01/07/21 JPMorgan
PVH Corp. price target raised to $101 from $88 at JPMorgan
PRPH ProPhase Labs
$6.29 /

+0.06 (+0.96%)

01/20/21 Dawson James
ProPhase Labs initiated with a Buy at Dawson James
SURF Surface Oncology
$7.25 /

-0.7 (-8.81%)

03/10/21 Wedbush
Surface Oncology risk/reward 'highly favorable' into data, says Wedbush
12/18/20 H.C. Wainwright
Surface Oncology price target raised to $15 from $11 at H.C. Wainwright
09/04/20
Fly Intel: Top five analyst initiations
09/04/20 H.C. Wainwright
Surface Oncology initiated with a Buy at H.C. Wainwright
CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

10/23/20 Oppenheimer
Casi Pharmaceuticals initiated with an Outperform at Oppenheimer
CLF Cleveland-Cliffs
$17.25 /

+1.01 (+6.22%)

02/03/21 Credit Suisse
U.S. Steel Industry upgraded to Overweight at Credit Suisse
01/26/21 GLJ Research
Cleveland-Cliffs downgraded to Hold on 'emerging headwinds' at GLJ Research
01/26/21 GLJ Research
Cleveland-Cliffs downgraded to Hold from Buy at GLJ Research
01/18/21 Exane BNP Paribas
Cleveland-Cliffs upgraded to Outperform from Neutral at Exane BNP Paribas
SLCA U.S. Silica
$11.88 /

+0.195 (+1.67%)

03/02/21 B. Riley
U.S. Silica price target raised to $15 from $4.35 at B. Riley Securities
01/04/21 Evercore ISI
U.S. Silica upgraded to Outperform from In Line at Evercore ISI
12/15/20 Citi
U.S. Silica upgraded to Neutral from Sell at Citi
07/22/20 B. Riley
U.S. Silica price target raised to $4.35 from $3 at B. Riley FBR
AVO Mission Produce
$18.05 /

-0.3801 (-2.06%)

03/23/21 Citi
Mission Produce downgraded to Neutral from Buy at Citi
03/15/21 DA Davidson
Mission Produce price target raised to $27 from $18 at DA Davidson
03/11/21
Fly Intel: Top five analyst downgrades
03/11/21 JPMorgan
Mission Produce downgraded to Neutral on valuation at JPMorgan
SURF Surface Oncology
$7.25 /

-0.7 (-8.81%)

SLCA U.S. Silica
$11.88 /

+0.195 (+1.67%)

RMO Romeo Power
$10.35 /

-0.53 (-4.87%)

PVH PVH Corp.
$100.25 /

+2.26 (+2.31%)

PHR Phreesia
$52.25 /

+1.46 (+2.87%)

NMTR 9 Meters Biopharma
$1.37 /

+0.035 (+2.63%)

MILE Metromile
$11.22 /

-0.21 (-1.84%)

LULU Lululemon
$317.46 /

+1.37 (+0.43%)

HYFM Hydrofarm
$53.10 /

+1.16 (+2.23%)

EDAP EDAP TMS
$9.55 /

-0.13 (-1.34%)

CRNX Crinetics
$15.45 /

-0.2 (-1.28%)

CLF Cleveland-Cliffs
$17.25 /

+1.01 (+6.22%)

CHWY Chewy
$80.39 /

+1.6 (+2.03%)

CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

CAAP Corporacion America Airport
$4.95 /

+0.24 (+5.10%)

BEEM Beam Global
$37.15 /

+1.85 (+5.24%)

BB BlackBerry
$9.34 /

+0.13 (+1.41%)

AVO Mission Produce
$18.05 /

-0.3801 (-2.06%)

APR Apria
$25.61 /

+0.63 (+2.52%)

  • 31
    Mar
  • 24
    Mar
  • 09
    Feb
  • 11
    Feb
  • 11
    Dec
  • 10
    Dec
  • 21
    Oct
  • 01
    Oct
  • 17
    Sep
  • 22
    Jul
  • 15
    Apr
LULU Lululemon
$317.46 /

+1.37 (+0.43%)

CHWY Chewy
$80.39 /

+1.6 (+2.03%)

BB BlackBerry
$9.34 /

+0.13 (+1.41%)

SURF Surface Oncology
$7.25 /

-0.7 (-8.81%)

RMO Romeo Power
$10.35 /

-0.53 (-4.87%)

PVH PVH Corp.
$100.25 /

+2.26 (+2.31%)

PRPH ProPhase Labs
$6.29 /

+0.06 (+0.96%)

PHR Phreesia
$52.25 /

+1.46 (+2.87%)

NMTR 9 Meters Biopharma
$1.37 /

+0.035 (+2.63%)

LULU Lululemon
$317.46 /

+1.37 (+0.43%)

HYFM Hydrofarm
$53.10 /

+1.16 (+2.23%)

CLF Cleveland-Cliffs
$17.25 /

+1.01 (+6.22%)

CHWY Chewy
$80.39 /

+1.6 (+2.03%)

CASI Casi Pharmaceuticals
$1.98 /

-0.01 (-0.50%)

BEEM Beam Global
$37.15 /

+1.85 (+5.24%)

BB BlackBerry
$9.34 /

+0.13 (+1.41%)

AVO Mission Produce
$18.05 /

-0.3801 (-2.06%)

APR Apria
$25.61 /

+0.63 (+2.52%)

RMO Romeo Power
$10.35 /

-0.53 (-4.87%)

PVH PVH Corp.
$100.25 /

+2.26 (+2.31%)

PRPH ProPhase Labs
$6.29 /

+0.06 (+0.96%)

PHR Phreesia
$52.25 /

+1.46 (+2.87%)

NMTR 9 Meters Biopharma
$1.37 /

+0.035 (+2.63%)

MILE Metromile
$11.22 /

-0.21 (-1.84%)

LULU Lululemon
$317.46 /

+1.37 (+0.43%)

HYFM Hydrofarm
$53.10 /

+1.16 (+2.23%)

CLF Cleveland-Cliffs
$17.25 /

+1.01 (+6.22%)

CHWY Chewy
$80.39 /

+1.6 (+2.03%)

CAAP Corporacion America Airport
$4.95 /

+0.24 (+5.10%)

BEEM Beam Global
$37.15 /

+1.85 (+5.24%)

BB BlackBerry
$9.34 /

+0.13 (+1.41%)

Earnings
Crinetics reports Q4 (EPS (66c), consensus (58c) » 16:27
03/30/21
03/30
16:27
03/30/21
16:27
CRNX

Crinetics

$15.45 /

-0.2 (-1.28%)

As of February 28 the…

As of February 28 the company had 33,028,876 common shares outstanding. "We are entering 2021 poised to achieve several key milestones that we believe will consolidate our position as a leader in the design and development of novel small molecule drugs for endocrine diseases," said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. "Our positive Phase 2 acromegaly data demonstrate the potential of orally administered paltusotine to replace injectable somatostatin receptor ligand (SRL) depots as the standard-of-care. With input from a recently completed FDA meeting, we have designed the paltusotine Phase 3 program to support its approval for all acromegaly patients who require pharmacotherapy, including both untreated patients and those switching from injected standard of care." Dr. Struthers continued, "Paltusotine's success and progress serve as a blueprint for our new therapeutic candidates in endocrinology. We plan to follow a similar path with CRN04777 and CRN04894, both of which recently entered Phase 1 proof-of-concept trials in healthy volunteers. Much like paltusotine's Phase 1 program, we've designed these trials to evaluate safety, drug-like pharmacokinetics, and corresponding pharmacodynamic effects on well-validated hormonal biomarkers for their respective indications. We look forward to reporting results from the Phase 1 trials later this year, and to the continued progression of our clinical and preclinical pipelines."

ShowHide Related Items >><<
CRNX Crinetics
$15.45 /

-0.2 (-1.28%)

CRNX Crinetics
$15.45 /

-0.2 (-1.28%)

11/24/20 Piper Sandler
Crinetics could take 'sizable share' in $3.1B market, says Piper Sandler
11/23/20 Cantor Fitzgerald
Crinetics price target raised to $42 from $38 at Cantor Fitzgerald
10/26/20 Piper Sandler
ACROBAT data improve odds of Phase 3 success for Crinetics, says Piper Sandler
10/14/20 JPMorgan
Crinetics resumed with a Neutral at JPMorgan
CRNX Crinetics
$15.45 /

-0.2 (-1.28%)

  • 15
    Apr
Earnings
Crinetics reports Q4 (EPS (66c), consensus (58c) » 16:27
03/30/21
03/30
16:27
03/30/21
16:27
CRNX

Crinetics

$15.45 /

-0.2 (-1.28%)

As of February 28 the…

As of February 28 the company had 33,028,876 common shares outstanding. "We are entering 2021 poised to achieve several key milestones that we believe will consolidate our position as a leader in the design and development of novel small molecule drugs for endocrine diseases," said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. "Our positive Phase 2 acromegaly data demonstrate the potential of orally administered paltusotine to replace injectable somatostatin receptor ligand (SRL) depots as the standard-of-care. With input from a recently completed FDA meeting, we have designed the paltusotine Phase 3 program to support its approval for all acromegaly patients who require pharmacotherapy, including both untreated patients and those switching from injected standard of care." Dr. Struthers continued, "Paltusotine's success and progress serve as a blueprint for our new therapeutic candidates in endocrinology. We plan to follow a similar path with CRN04777 and CRN04894, both of which recently entered Phase 1 proof-of-concept trials in healthy volunteers. Much like paltusotine's Phase 1 program, we've designed these trials to evaluate safety, drug-like pharmacokinetics, and corresponding pharmacodynamic effects on well-validated hormonal biomarkers for their respective indications. We look forward to reporting results from the Phase 1 trials later this year, and to the continued progression of our clinical and preclinical pipelines."

ShowHide Related Items >><<
CRNX Crinetics
$15.45 /

-0.2 (-1.28%)

CRNX Crinetics
$15.45 /

-0.2 (-1.28%)

11/24/20 Piper Sandler
Crinetics could take 'sizable share' in $3.1B market, says Piper Sandler
11/23/20 Cantor Fitzgerald
Crinetics price target raised to $42 from $38 at Cantor Fitzgerald
10/26/20 Piper Sandler
ACROBAT data improve odds of Phase 3 success for Crinetics, says Piper Sandler
10/14/20 JPMorgan
Crinetics resumed with a Neutral at JPMorgan
CRNX Crinetics
$15.45 /

-0.2 (-1.28%)

  • 15
    Apr
Hot Stocks
Crinetics presents on product pipeling at ENDO 2021 » 07:25
03/22/21
03/22
07:25
03/22/21
07:25
CRNX

Crinetics

$16.39 /

+0.18 (+1.11%)

Crinetics Pharmaceuticals…

Crinetics Pharmaceuticals provided details of four presentations that were made at the Endocrine Society's annual ENDO 2021 congress on the company's product pipeline. A late-breaking e-poster and oral presentation provided details of the preclinical findings supporting the company's development of CRN04894 and CRN04777. Crinetics presented a late-breaking e-poster describing the potential of SST5 receptor agonists to regulate glucose-stimulated insulin secretion from human islet cells. One of somatostatin's roles in maintaining blood glucose concentrations is to regulate insulin secretion, yet the lack of highly selective agonists has previously hampered efforts to identify the role of the individual somatostatin receptor subtypes in this process. In its preclinical efforts, Crinetics observed that SST5 receptor agonists were potent inhibitors of insulin secretion in the healthy pancreas and under conditions that stimulated excess insulin secretion. Based on these results, the company believes that a selective SST5 agonist may have therapeutic value in the treatment of congenital HI, which is a condition associated with dysregulated insulin secretion. Based on these preclinical findings, Crinetics advanced CRN04777, an investigational, oral nonpeptide SST5 agonist, into a clinical program for congenital HI. CRN04777 is currently being evaluated in a Phase 1 trial designed to evaluate safety, pharmacokinetics, and clinical proof-of-concept by employing well-established methods for evaluating insulin secretion. Crinetics also discussed preclinical results related to CRN04894, an investigational, oral nonpeptide ACTH antagonist, during a live oral presentation at ENDO 2021. CRN04894 recently advanced into a Phase 1 clinical program in healthy volunteers that is designed to evaluate safety, pharmacokinetics, and clinical proof-of-concept by measuring the ability of CRN04894 to suppress cortisol, cortisol precursors and adrenal androgens following exogenous ACTH stimulation. Preclinical data featured in the oral presentation showed that repeat dosing of CRN04894 suppressed plasma corticosterone levels in a robust and dose-dependent manner in animal models of ACTH excess. Results also showed that after seven days, the weight gain and adrenal gland hypertrophy caused by excess ACTH were reduced. This evidence supports the further evaluation of CRN04894 in conditions such as Cushing's disease and congenital adrenal hyperplasia, which are associated with excessive ACTH. In addition to the company's pipeline programs, Crinetics presented two posters on paltusotine, for the treatment of acromegaly, including results from the Phase 2 ACROBAT Edge study. Edge was a single-arm study designed to evaluate the impact of switching patients with acromegaly from monthly injected somatostatin receptor ligands to paltusotine, an experimental oral, once-daily, nonpeptide SST2 receptor agonist. Edge enrolled individuals who had not achieved normal insulin-like growth factor-1 levels despite receiving long-acting octreotide or lanreotide. As previously reported, after 13 weeks of treatment 20 of 23 participants who completed the dosing period maintained their IGF-1 to levels within 20% of their baseline or lower. The most common treatment-emergent adverse events included: headache, arthralgia, fatigue, peripheral swelling, paresthesia and hyperhidrosis. There were no discontinuations due to adverse events and no treatment-related serious adverse events. Crinetics plans to advance paltusotine into a Phase 3 clinical program in acromegaly in the first half of 2021 using a new tablet formulation. Results of a Phase 1 pharmacokinetic study reported at ENDO 2021 demonstrated that this new once-daily tablet formulation of paltusotine had a fasting requirement of only 0.5-1 hour, compared to the 2-hour requirement of the prior capsule formulation. The tablet formulation also showed improved dose-proportional exposure up to 80 mg, which offers the potential for greater dosing flexibility compared to the prior formulation. In addition, the new tablet formulation was observed to be less sensitive to effects of acid lowering drugs, such as proton pump inhibitors. In planned Phase 3 studies of paltusotine, the new tablet formulation will be administered with a 1-hour post-dose fast without the exclusion of acid lowering drugs. less sensitive to effects of acid lowering drugs, such as proton pump inhibitors. In planned Phase 3 studies of paltusotine, the new tablet formulation will be administered with a 1-hour post-dose fast without the exclusion of acid lowering drugs.

ShowHide Related Items >><<
CRNX Crinetics
$16.39 /

+0.18 (+1.11%)

CRNX Crinetics
$16.39 /

+0.18 (+1.11%)

11/24/20 Piper Sandler
Crinetics could take 'sizable share' in $3.1B market, says Piper Sandler
11/23/20 Cantor Fitzgerald
Crinetics price target raised to $42 from $38 at Cantor Fitzgerald
10/26/20 Piper Sandler
ACROBAT data improve odds of Phase 3 success for Crinetics, says Piper Sandler
10/14/20 JPMorgan
Crinetics resumed with a Neutral at JPMorgan
CRNX Crinetics
$16.39 /

+0.18 (+1.11%)

  • 15
    Apr
Over a quarter ago
Hot Stocks
Crinetics advances CRN04894 into Phase 1 study » 07:26
02/04/21
02/04
07:26
02/04/21
07:26
CRNX

Crinetics

$15.37 /

+0.63 (+4.27%)

Crinetics Pharmaceuticals…

Crinetics Pharmaceuticals announced that CRN04894, the company's lead adrenocorticotropic hormone antagonist for the treatment of diseases associated with excess ACTH such as Cushing's disease and congenital adrenal hyperplasia, has advanced into the clinic. Based on encouraging preclinical results, Crinetics has initiated a double-blind, randomized, placebo-controlled Phase 1 study of this orally administered, nonpeptide small molecule drug candidate in healthy volunteers. This study will assess the safety and tolerability of single and multiple doses of CRN04894 and will measure the effect of CRN04894 on suppression of cortisol, cortisol precursors, and adrenal androgens following exogenous ACTH stimulation.

ShowHide Related Items >><<
CRNX Crinetics
$15.37 /

+0.63 (+4.27%)

CRNX Crinetics
$15.37 /

+0.63 (+4.27%)

11/24/20 Piper Sandler
Crinetics could take 'sizable share' in $3.1B market, says Piper Sandler
11/23/20 Cantor Fitzgerald
Crinetics price target raised to $42 from $38 at Cantor Fitzgerald
10/26/20 Piper Sandler
ACROBAT data improve odds of Phase 3 success for Crinetics, says Piper Sandler
10/14/20 JPMorgan
Crinetics resumed with a Neutral at JPMorgan
CRNX Crinetics
$15.37 /

+0.63 (+4.27%)

  • 15
    Apr
Hot Stocks
Crinetics initiates Phase 1 study of CRN04777 for congenital HI » 07:23
02/03/21
02/03
07:23
02/03/21
07:23
CRNX

Crinetics

$14.68 /

+0.66 (+4.71%)

Crinetics Pharmaceuticals…

Crinetics Pharmaceuticals announced the initiation of a Phase 1 study of CRN04777, an oral, nonpeptide somatostatin receptor type 5 agonist being developed as a treatment for congenital hyperinsulinism. Congenital HI is a rare genetic disease associated with dysregulated insulin production in which excess insulin produces life-threatening hypoglycemia (low blood glucose) beginning at birth. The purpose of this study is to evaluate the safety and tolerability of CRN04777 in healthy adult volunteers. In addition, the study is designed to test the mechanism of action of CRN04777 by measuring its ability to suppress insulin secretion in healthy volunteers following stimulation with either glucose or a sulfonylurea, an agent that increases the secretion of insulin.

ShowHide Related Items >><<
CRNX Crinetics
$14.68 /

+0.66 (+4.71%)

CRNX Crinetics
$14.68 /

+0.66 (+4.71%)

11/24/20 Piper Sandler
Crinetics could take 'sizable share' in $3.1B market, says Piper Sandler
11/23/20 Cantor Fitzgerald
Crinetics price target raised to $42 from $38 at Cantor Fitzgerald
10/26/20 Piper Sandler
ACROBAT data improve odds of Phase 3 success for Crinetics, says Piper Sandler
10/14/20 JPMorgan
Crinetics resumed with a Neutral at JPMorgan
CRNX Crinetics
$14.68 /

+0.66 (+4.71%)

  • 15
    Apr
Hot Stocks
Crinetics sets out 2021 goals at J.P. Morgan Healthcare Conference » 07:48
01/06/21
01/06
07:48
01/06/21
07:48
CRNX

Crinetics

$13.30 /

-0.65 (-4.66%)

Crinetics Pharmaceuticals…

Crinetics Pharmaceuticals announced that company management will participate in the 39th annual J.P. Morgan Healthcare Conference, which is taking place in a virtual format. Scott Struthers, Ph.D., Founder & CEO of Crinetics, will present a company update on Wednesday, January 13th at 1:30 pm Pacific Time. A live audio webcast of Dr. Struthers' presentation may be accessed on the Events section of the company's website or directly on the J.P. Morgan virtual meeting platform. During his presentation, Dr. Struthers will discuss Crinetics' key priorities and anticipated milestones for 2021, including initiating the Phase 3 program for paltusotine for the treatment of acromegaly, initiating clinical trials for paltusotine in patients with carcinoid syndrome as well as for two new drug candidates for congenital hyperinsulinism and diseases of excess adrenocorticotropic hormone. To support the company's growing pipeline, Crinetics has expanded its development and medical teams with the appointments of several additional clinical endocrinology experts, increasing the company's total headcount to 90 with plans for continued hiring in 2021. Paltusotine for Acromegaly: Crinetics expects to hold an end-of-Phase-2 meeting with the FDA in the first quarter of 2021 and start its Phase 3 program in the first half of 2021. Crinetics intends to use a new, improved tablet formulation of paltusotine in the Phase 3 program for acromegaly. This formulation is designed to provide convenient once-daily administration but enable a reduced fasting requirement and improved dose-proportional exposure compared to the prior formulation. In addition, the new tablet formulation is designed to enable the administration of paltusotine with commonly used proton pump inhibitors. Paltusotine for Carcinoid Syndrome: Crinetics expects to advance paltusotine into a clinical study in patients with carcinoid syndrome due to neuroendocrine tumors. Injected SRLs are the standard of care for patients with carcinoid syndrome, but many patients become increasingly resistant to treatment over time, requiring increased dosage of depot preparations or the addition of short-acting analogs. Crinetics believes that an oral therapy with a long half-life and dose-proportional exposure would be a useful option for these patients, if approved. CRN04894: A Phase 1 study evaluating the ability of CRN04894 to suppress ACTH-stimulated cortisol secretion in healthy volunteers is planned to commence in January 2021. Results are expected in the first half of 2021 and, if positive, may provide proof-of-concept data supporting further evaluation of CRN04894 in the treatment of diseases associated with excess ACTH such as Cushing's disease and congenital adrenal hyperplasia. CRN04894 is an investigational, oral, selective ACTH antagonist designed to block the action of excess ACTH on the adrenal gland resulting in excess cortisol in Cushing's disease and excess adrenal androgens in CAH. CRN04777: A Phase 1 study evaluating the ability of CRN04777 to reduce stimulated insulin secretion in healthy volunteers is planned to commence in February 2021. Data is expected in mid-2021 and, if positive, the results of this trial may provide proof-of-concept data to support further evaluation of CRN04777 in the treatment of children with CHI. CRN04777 is an investigational, oral, selective non-peptide SST5 receptor agonist designed to reduce insulin secretion and thereby correct the life-threatening hypoglycemia that affects these children. In 2021, Crinetics expects to continue its drug discovery efforts with programs to identify drug candidates for hyperparathyroidism, nonfunctional pituitary adenomas and polycystic kidney disease, among other indications. This pipeline expansion is intended to drive continued growth and value for stakeholders.

ShowHide Related Items >><<
CRNX Crinetics
$13.30 /

-0.65 (-4.66%)

CRNX Crinetics
$13.30 /

-0.65 (-4.66%)

11/24/20 Piper Sandler
Crinetics could take 'sizable share' in $3.1B market, says Piper Sandler
11/23/20 Cantor Fitzgerald
Crinetics price target raised to $42 from $38 at Cantor Fitzgerald
10/26/20 Piper Sandler
ACROBAT data improve odds of Phase 3 success for Crinetics, says Piper Sandler
10/14/20 JPMorgan
Crinetics resumed with a Neutral at JPMorgan
CRNX Crinetics
$13.30 /

-0.65 (-4.66%)

  • 15
    Apr
CRNX Crinetics
$13.30 /

-0.65 (-4.66%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.